Advertisement
UK markets open in 4 hours 8 minutes
  • NIKKEI 225

    39,543.37
    -197.07 (-0.50%)
     
  • HANG SENG

    16,589.25
    -147.87 (-0.88%)
     
  • CRUDE OIL

    82.56
    -0.16 (-0.19%)
     
  • GOLD FUTURES

    2,165.30
    +1.00 (+0.05%)
     
  • DOW

    38,790.43
    +75.66 (+0.20%)
     
  • Bitcoin GBP

    51,518.98
    -1,972.08 (-3.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    16,103.45
    +130.27 (+0.82%)
     
  • UK FTSE All Share

    4,218.89
    -3.20 (-0.08%)
     

AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?

AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the Alexion acquisition is a good deal for AstraZeneca. Keith Speights: AstraZeneca has experienced multiple problems with the launch of its COVID-19 vaccine and we're not going to get into all of those problems but there's more news non-COVID related for AstraZeneca now.